FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Provenge | Dendreon

Dendreon shares routed by Medicare Provenge review news


Shares of Dendreon (DNDN) took a nasty hit on Wednesday after Medicare officials announced plans to review its new prostate cancer vaccine to see whether the federal program should pay to provide it for seniors. Medicare's policies are considered very influential with payers, and investors pushed Dendreon's high flying shares down 23 percent on fears that an obstacle at the agency could blunt Provenge's blockbuster sales potential.

Medicare plans to have an external group determine if the cancer vaccine is "reasonable and necessary" for the 45 million seniors in the program. And it could take almost a year before it delivers its decision. For its part, Dendreon said it welcomed the review, noting that local Medicare contractors who manage the program can still provide it to patients.

For now, though, Dendreon's biggest challenge has been to ramp up production for Provenge to begin meeting the enormous demand for the product, which costs $93,000 for a three-infusion course. Bloomberg has reported that Dendreon can only provide enough of the therapeutic vaccine to treat two percent of the patients who can qualify to benefit from it.

- read the story from Dow Jones
- check out the report from Reuters
- here's the story from the Wall Street Journal on supply issues

Related Articles:
CMS looking into whether to pay for Provenge
Dendreon: Provenge to cost $93K for full course
Dendreon scrambles to boost Provenge production

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Provenge   Dendreon  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.